bibliographicCitation |
Albanesi M, Mancardi DA, Macdonald LE, Iannascoli B, Zitvogel L, Murphy AJ, Daëron M, Leusen JH, Bruhns P. Cutting edge: FcγRIII (CD16) and FcγRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma. J Immunol. 2012 Dec 15;189(12):5513–7. doi: 10.4049/jimmunol.1201511. PMID: 23150715. |